Genovis has announced the successful divestment of its antibody business to Leinco Technologies, a developer of antibodies for research and diagnostics.

The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business, it states. The antibody business, while valuable, was deemed non-core to the company’s long-term growth strategy.

Financial terms of the deal were not disclosed.

“We are pleased to have found a strong partner in Leinco Technologies to take over our antibody business,” says Fredrik Olsson, CEO of Genovis. “This divestment allows us to dedicate our resources to our core enzyme business, where we see significant growth potential. We believe that under Leinco’s ownership, the antibody business will thrive and continue to serve its customers with the same commitment to quality and innovation.”

“We are excited to integrate Genovis’s antibody assets into our portfolio,” says Pat Leinert Sr., CEO of Leinco Technologies. “This acquisition strengthens our position in the antibody market and allows us to offer an even broader range of innovative products to our customers. We look forward to building on Genovis’s legacy of excellence and delivering these unique antibodies to researchers and clinicians worldwide.”

Photo of Fredrik Olsson, CEO of Genovis: Christian Andersson